Subsequently, to understand the pathophysiological role of METTL16 in vivo, we established subcutaneous xenograft tumor models with stable METTL16 overexpression or METTL16 knockdown in BCPAP and K1 cells, where palpable tumors were formed around the 5th day. The gene discussed is METTL16; the disease is neoplasm.